Table 1.

Patient characteristics

Patient numberAgeGenderTumor typeDose levelDuration of treatment, moNumber of cycles completedTime to progression, moBest responseReason off treatment
161MaleUrothelial04.24NAaSDMD decision
277MaleUrothelial01.21NANEToxicity
350MaleUrothelial05.665.6SDPD
470MaleUrothelial−113.81313.8CRPD
549FemaleSCLC−11.82NASDPD
657FemaleAdrenal cortex−112.61313.0SDMD decision
759FemaleNSCLC−12.02NASDToxicity
861FemaleAtypical carcinoid of lung−11.921.8PDPD
950MaleUrothelial−13.943.8SDPD

Abbreviations: CR, complete response; NE, not evaluable; PD, progressive disease; PR, partial response; SD, stable disease; NA, not applicable.

  • aPatient had only one disease assessment and was reported to have SD at 3.8 months.